Protect and return value

Exclusively focused on managing the financial collaborations with GSK and Vanda

Learn more

Anaptys completed the spin-off of First Tracks Biotherapeutics, its biotech operations, on April 20, 2026. Learn more about First Tracks Bio.

unique illustration of a circle of molecules

Recent news & events

Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference

AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Chris Murphy, chief financial officer, is scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, Sept. 15, 2026. The presentation is scheduled to begin at 3:30pm ET.
Read more

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
Read more

Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced the appointment of Christopher Murphy as Chief Financial Officer and Owen Hughes as a member of its Board of Directors.
Read more